Clinical Research Directory
Browse clinical research sites, groups, and studies.
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Sponsor: Massachusetts General Hospital
Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Official title: BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-11-24
Completion Date
2027-06
Last Updated
2025-12-30
Healthy Volunteers
No
Conditions
Interventions
Smartwatch activity and body composition monitor
Participants will be provided a smartwatch to monitor their exercise and body composition
General guidance on recommended exercise
Participants will receive general guidance on recommended exercise
Locations (1)
Diabetes Research Center
Boston, Massachusetts, United States